Claritas to take majority stake in Spain's Qubiotech to build independent PET platform
What's the deal? Claritas NucMedDealroom has a profile for this one. Try Dealroom → Technologies, a subsidiary of Claritas HealthTechDealroom has a profile for this one. Try Dealroom →, has signed heads of terms to acquire a majority stake in Qubiotech Health IntelligenceDealroom has a profile for this one. Try Dealroom →, the Spanish developer of the neuroCloud brain PET platform. The deal value was not disclosed. It would combine Claritas's cleared PET image enhancement and oncology quantification software with Qubiotech's brain-imaging analytics into one platform spanning oncology and neurology.
Why now? PET scans increasingly decide treatment in two areas. In oncology, theranostics uses PET to select patients for radiopharmaceutical therapy and track response; in neurology, amyloid-targeting Alzheimer's therapies make brain PET the gateway to treatment and the tool for monitoring it.
What's the endgame? Much of the quantitative software hospitals use is tied to a scanner maker's ecosystem. Claritas is pitching a vendor-neutral alternative that runs on standard DICOM, on site, with no new hardware, across any scanner and tracer.
What each side brings: Claritas's iPET enhances images from any radionuclide and is cleared in the US, Brazil, Australia, Singapore, and India, with CE and UKCA marking pending; its iPETcertum adds FDA-cleared automated segmentation. Qubiotech's neuroCloud is CE-marked and delivers automated brain PET analysis, including amyloid Centiloid scoring for all three approved amyloid tracers, without MRI. Qubiotech also gives Claritas a research and development centre and regulatory base in Europe.
What's the pitch? For hospitals, the combination offers one independent supplier for image quality and quantification across oncology, theranostics, and neurology. For drug developers, it offers a single isotope-agnostic imaging partner using the same methods across every trial site.
"PET is becoming the measurement that decides treatment, in cancer and in Alzheimer's disease," said Chetan Baxi, chief executive officer of Claritas HealthTech. "With iPET, iPETcertum and now neuroCloud under one roof, Claritas can deliver that from whole body to brain, independently of any scanner maker."
What could go wrong? The announcement is preliminary rather than a completed deal, and significance will hinge on closing the transaction and demonstrating adoption. neuroCloud is still pursuing FDA clearance, leaving the US market unproven.
The signal: The tie-up reflects a competitive push for standardised PET quantification as Alzheimer's therapies raise the stakes on patient selection. In August 2026, Cortechs.ai's NeuroQuant PET won FDA clearance for automated brain-PET quantification, underscoring a crowding field where vendor neutrality is Claritas's bet to stand apart.
Read more: manilatimes.net
Image credit: Generated with Gemini
